Ask A Lawyer
Talk to a Keppra Lawyer for a free case review.
In 2007, generic drug manufacturers netted more than $58 billion in sales in the United States. The demand for generic drugs is driven by healthcare insurance companies, consumers, and pharmacies, which generally enjoy substantially higher profit margins when they substitute a generic medication for the branded medication.
In December 2009, Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets, 1000 mg.
Levetiracetam Tablets are the generic version of UCB Pharma's antiepileptic Keppra®.
This additional strength of Levetiracetam Tablets complements Mylan's already approved and marketed strengths of 250 mg, 500 mg, and 750 mg Levetiracetam Tablets, 1000 mg had U.S. sales of approximately $136 million for the 12 months ending Sept. 30 and shipped immediately.
After the Mylan generic AED LVT came on the market, complaints from consumers, consumer watchdog groups, and healthcare professionals came pouring in, not only to the FDA but to numerous consumer and special interest groups.
Patients whose seizures had been effectively controlled for months if not years were experiencing seizures shortly after being switched to the Mylan generic version of Keppra.
Have you or a loved one suffered needlessly from taking Mylan LVT, the generic version of Keppra? Has your life or the lives of your loved ones been traumatized by another seizure when the Keppra brand AED formerly kept seizures at bay? If the answer is yes, take action now and contact an unsafe drug law firm to determine whether or not you qualify for a contingency-fee based lawsuit.